Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol

Antiviral Research

Volumn 81, Issue 2, 2009, Pages 132-140

  Leneva, Irina A ^a,b   Russell, Rupert J ^c   Boriskin, Yury S ^d   Hay, Alan J ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b Russian Chemical and Pharmaceutical Institute   (Russian Federation)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

Author keywords

Arbidol; Arbidol resistant mutants; Influenza haemagglutinin; Inhibition of membrane fusion; Low pH conformational change

Indexed keywords

ARBIDOL; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC REASSORTMENT; HEMOLYSIS; HUMAN; HUMAN CELL; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS B; MEMBRANE FUSION; MOLECULAR DOCKING; NONHUMAN; PH; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS TITRATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; HEMAGGLUTININS, VIRAL; INDOLES; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN CONFORMATION; REASSORTANT VIRUSES;

CERCOPITHECINE HERPESVIRUS 1; ORTHOMYXOVIRIDAE;

EID: 58249083139     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.10.009     Document Type: Article

References (51)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., and Uyeki T.M. Update on avian influenza A(H5N1) virus infection in humans. N. Engl. J. Med. 358 (2008) 261-273
2. Beliaev A.L., Burtseva E.I., Slepushkin A.N., Beliaeva N.A., Nosik N.N., Lavrukhina L.A., Maksimova L.N., Feklisova L.V., Shibekova V.M., Danina N.F., Tselipanova E.E., Bylinkina S.A., Voitsekhovskaya E.M., and Sominina A.A. Arbidol-a new drug for prevention of influenza and acute viral respiratory infections in children. Vestnik RAMN (Russian) 8 (1996) 34-37
3. Belshe R.B., Smith H.M., Hall C.B., Betts R., and Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62 (1988) 1508-1512
4. Bodian D.L., Yamasaki R.B., Buswell R.L., Stearns J.F., White J.M., and Kuntz I.D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32 (1993) 2967-2978
5. Boriskin Y., Leneva I., Pecheur E., and Polyak S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15 (2008) 997-1005
6. Burtseva E., Shevchenko E., Leneva I., Shuster A., Merkulova L., Zaplatnikov A., and Slepushkin A. The sensitivity to arbidol of epidemic strains of influenza A and B viruses isolated in Russia during season 2004-2005. Vopr. Virusol. (Russian) 2 (2007) 24-26
7. Cianci C., Yu K.L., Dichino D.D., Harte W., Deshpande M., Luo G., Colonno R.J., Meanwell N.A., and Krystal M. pH-Dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion. J. Virol. 73 (1999) 1785-1794
8. Couch R.B., Keitel W.A., Cate T.R., Quarles J.A., Taber L.A., and Glezen W.P. Prevention of influenza virus infection by current influenza virus vaccines. In: Brown L.E., Hampson A.W., and Webster R.G. (Eds). Options for the Control of Influenza III (1996), Elsevier, Amsterdam 97-106
9. Daniels R.S., Downie J.C., Hay A.J., Knossow M., Skehel J.J., Wang M.L., and Wiley D.C. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 40 (1985) 431-439
10. De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. 5 (2006) 1015-1024
11. De Jong J.C., Claas E.C., Osterhaus A.D.M.E., Webster R.G., and Lim W.L. A pandemic warning?. Nature 389 (1997) 554
12. De Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.H., Nguyen B.H., Beld M., Le T.P., Truong H.K., Nguyen V.V., Tran T.H., Do Q.H., and Farrar J. Fatal avian influenza A(H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352 (2005) 686-691
13. Douglas R.G. Prophylaxis and treatment of influenza. New Engl. J. Med. 322 (1990) 443-450 (Review)
14. Drinevskiy V.P., Osidak L.V., Natsina V.K., Afanasyeva O.I., Milkint K.K., Danini G.V., Ispolatova A.V., Koreniako I.E., Karelina N.N., Marinich I.G., and Boldasov V.K. Chemiotherapeutics for treatment of influenza and other viral respiratory tract infections in children. Antibiot. Chemother. (Russian) 9 (1998) 29-34
15. Fadeeva N.I., Leneva I.A., Panischeva E.K., Bousse T.L., Khristova M.L., Granik V.G., and Kharitonenkov I.G. Inhibitors of early stages of virus-cell interaction among derivatives of 3-carbotoxy-5-oxy-6-bromindole. Chem. Pharm. J. (Russian) 9 (1992) 9-11
16. Fediakina I., Leneva I., Iamnikova S., Lvov D., Glushkov R., and Shuster A. Sensitivity of influenza A/H5 viruses isolated from wild birds on the territory of Russia to arbidol in the cultured MDCK cells. Vopr. Virusol. (Russian) 50 6 (2005) 32-35
17. Glushkov R.G. Arbidol. Drugs Future 17 (1992) 1079-1081
18. Glushkov R.G., Fadeeva N.I., Leneva I.A., Gerasina S.F., Budanova L.I., Sokolova N.D., Stebaeyeva L.F., and Fedyakina I.T. Molecular-biological features of the action of arbidol, a new antiviral drug. Chem. Pharm. J. (Russian) 2 (1992) 8-15
19. Grambas S., and Hay A.J. Maturation of influenza A virus hemagglutinin-estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 190 (1992) 11-17
20. Grambas S., Benett M.S., and Hay A.J. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza virus. Virology 191 (1992) 541-549
21. Gubareva L.V., Bethell R., Hart G.J., Murti K.G., Penn C.R., and Webster R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitors 4-guanidino-neu5Ac2en. J. Virol. 70 (1996) 1818-1827
22. Guskova T.A., and Glushkov R.G. Efficacy and safety of arbidol in treating and Prophylaxis of influenza: clinical trials. Arbidol-A New Antiviral, Immunomodulator, Interferon Inducer (Russian) (1999), Timotek, Moscow pp. 63-76
23. Hay A.J. Amantadine and rimantadine-mechanisms. In: Richman D.D. (Ed). Antiviral Drug Resistance (1996), John Wiley and Sons, Ltd., New York 43-57
24. Hayden F.G. Amantadine and rimantadine-clinical aspects. In: Richman D.D. (Ed). Antiviral Drug Resistance (1996), John Wiley and Sons, Ltd., New York 59-77
25. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., and Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N. Engl. J. Med. 25 (1997) 874-880
26. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., and Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282 (1999) 1240-1246
27. Hoffman L.R., Kuntz I.D., and White J.M. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J. Virol. 71 (1997) 8808-8820
28. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., and Stevens R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interactions in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119 (1997) 681-690
29. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., and Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur. Surveill. 13 5 (2008)
30. Leneva I.A., Fadeeva N.I., Fedyakina I.T., Guskova T.A., Khristova M.L., Sokolova M.V., and Kharitonenkov I.G. Study of arbidol, a new anti-influenzal drug, using immuno-enzymated detection of virus specific antigens. Chem. Pharm. J. (Russian) 9 (1994) 4-15
31. Leneva I., Fediakina I., Guskova T., and Glushkov R. Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A. Ter. Arkh. (Russian) 77 (2005) 84-88
32. Luo G., Colonno R., and Krystal M. Characterization of a hemagglutinin-specific inhibitor of influenza virus. Virology 226 (1996) 66-76
33. Luo G., Torri A., Harte W.E., Danetz S., Cianci C., Tiley L., Day S., Mullaney D., Yu K.L., Ouellet C., Dextraze P., Meanwell N., Colonno R., and Krystal M. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. 71 (1997) 4062-4070
34. Lvov D., Fediakina I., Schelkanov M., Prilipov A., Deriabin P., and Galegov G. In vitro effects of antiviral drugs on the reproduction of highly pathogenic influenza A/H5N1 virus strains that induce epizooty among poultry in the summer of 2005. Vopr. Virusol. (Russian) 2 (2006) 20-22
35. Meanwell N.A., and Krystal M. Taking aim at a moving target: inhibitors of influenza virus. I. Virus adsorption, entry and uncoating. Drug Discov. Today 1 (1996) 316-324
36. Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., Trottier S., Carewicz O., Mercier C.H., Rode A., Kinnersley N., and Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 355 (2000) 1845-1850
37. Ohmit S.E., Arden N.H., and Monto A.S. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A(H3N2) epidemic. J. Am. Geriatr. Soc. 47 (1999) 165-171
38. Plotch S.J., O'Hara B.O., Morin J., Palant O., LaRocque J., Bloom J.D., Lang S.A., DiGrandi M.J., Bradley M., Nilakantan R., and Gluzman Y. Inhibiton of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J. Virol. 73 (1999) 140-151
39. Powers D.C., and Belshe R. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J. Infect. Dis. 167 (1993) 584-592
40. Ruben F.L. Now and future influenza vaccines. Inf. Dis. Clin. North Am. 4 (1990) 1-10 (Review)
41. Russell R.J., Gamblin S.J., Haire L.F., Stevens D.J., Xiao B., Ha Y., and Skehel J.J. H1 and H7 influenza haemaglutinin structures extend a structural classifications of haemaglutinin subtypes. Virology 352 (2004) 287-296
42. Shi L., Xiong U., He J., Deng H., Li Q., Zhong O., Hou W., Cheng L., Xiao H., and Yang Z. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch. Virol. 152 8 (2007) 1447-1455
43. Shumilov V.I., Shuster A.M., Lobastov S.P., Shevtsov V.A., Mednikov B.L., Piiavskii S.A., and Litus V.I. Efficacy of arbidol in prophylaxis and treatment of acute respiratory viral infections in servicemen. Voen. Med. Zh. (Russian) 9 (2002) 51-53
44. Sidwell R.W., Huffman J.H., Barnard D.L., Bailey K.W., Wong M.N., Morrison A., Syndergaard T., and Kim C.U. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antivir. Res. 37 (1998) 107-120
45. Skehel J.J., Bayley P.M., Brown E.B., Martin S.R., Waterfield M.D., White J.M., Wilson I.A., and Wiley D.C. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 968-972
46. Sugrue R.J., Bahadur G., Zambon M.C., Hall-Smith M., Douglas A.R., and Hay A.J. Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J. 11 (1990) 3469-3476
47. Tai C.Y., Escarpe P.A., Sidwell R.W., Williams M.A., Lew W., Kim C.U., and Mendel D.B. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antimicrob. Agents Chemother. 42 (1998) 3234-3241
48. Uchaikin V., Kharlamova S., and Cheshik S. Arbidol and amixin application as an etiotropic influenza and common cold therapy in children. Pediatrics (Russian) 5 (2004) 73-77
49. von Itzstein M., Wu W.-Y., Kok G.K., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smithe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., and Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus protection. Nature 363 (1993) 418-423
50. Wharton S.A., Belshe R.B., Skehel J.J., and Hay A.J. Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J. Gen. Virol. 75 (1994) 945-948
51. Zlydnikov D.M., Kubar O.I., Kovaleva T.P., and Kamforin L.E. Study of rimantadine in the USSR: a review of the literature. Rev. Infect. Dis. 3 (1981) 408-421 (Review)